Navigating the Evolving Bladder Cancer Landscape: The Nurse’s Role in Improving Patient Outcomes
Join our expert Nursing faculty as they review immune checkpoint inhibitor (ICI) data across bladder cancer treatment, from NMIBC to MIBC to locally advanced/metastatic disease. Our experts also will provide an understanding of effective therapeutic sequencing of platinum-based chemotherapy, ICIs, targeted therapies, and antibody-drug conjugates, as well as integration of novel combinatorial regimens in both first-line and later lines of therapy. Finally, our expert faculty will conclude with nursing-centric insights for anticipating and managing immune-mediated adverse events (imAEs) in patients receiving ICIs to deliver effective nursing care to their patients with bladder cancer.
This activity is designed to meet the educational needs of oncology nurses and nurse practitioners attending local ONS Chapter Meetings across the U.S.
- Appraise the expanding clinical trial evidentiary base across all stages of the bladder cancer disease continuum, including newly-approved indications, recently-reported data, and current consensus guideline recommendations for treatment of NMIBC, MIBC, and locally advanced/mUC.
- Examine the evolving bladder cancer management calculus, with a focus on evidence-based treatment sequencing strategies and/or combinatorial regimens incorporating platinum chemotherapy, immune checkpoint inhibitors, targeted therapies, and antibody-drug conjugates.
- Review practical patient counseling strategies related to the safety, efficacy, and therapeutic rationale of novel treatments in bladder cancer, with an emphasis on the provision of adaptive emotional support infrastructures.
- Identify immune-mediated adverse events (imAEs) that may occur in patients with bladder cancer receiving immune checkpoint inhibitors, either as monotherapy or in combination, and implement adaptive imAE anticipation, recognition, and management strategies.
Presented by Creative Educational Concepts, LLC.
Supported through independent educational grants from AstraZeneca and Merck.
Welcome and Introductions/Pre-test
Key Teaching Points:
- How to apply the latest clinical trial data and expert consensus guidelines when designing a treatment strategy using immune checkpoint inhibitors across the totality of the bladder cancer disease continuum (i.e., NMIBC, MIBC, locally advanced/metastatic)
- How to appropriately sequence platinum-based chemotherapy, IO, FGFR inhibitors, and antibody-drug conjugates in patients with locally advanced and metastatic disease
- Comparative safety and efficacy profiles (based on current data) and therapeutic rationale of available therapies
- The clinical utility and paradigmatic placement of emerging combinatorial regimens (i.e., ICI+ICI, ICI+chemo, ICI+targeted therapy, ICI+ADC, ICI+BCG, etc.), with a particular focus on novel front line options
- Using patient-specific and disease-specific factors to execute appropriate patient selection for treatment
- Employing checkpoint inhibitors as a therapeutic option for the high-risk NMIBC patient with BCG-unresponsive disease, and/or as neoadjuvant/adjuvant modalities in the MIBC setting
- Optimal treatment sequencing for patients who experience post-platinum and post–anti-PD-1/L1 progression
- Developing practical plans to proactively manage immune-mediated adverse events (imAEs) that may occur, and if they do occur, how to determine whether to stop IO therapy, and when/if to reinitiate therapy once the imAE has been managed
- Pivotal patient counseling principles and best practices
- Key imAE teaching points and practical tools
- Foundational tenets of delivering timely and clinically-appropriate emotional support to patients/caregivers
Conversations with the Experts/Audience /Q&A/Post-test
Anne Lizardi-Calvaresi, DNP, RNFA
Director of Clinical Operations
Sidney Kimmel Cancer Center
Thomas Jefferson University
It is the policy of Creative Educational Concepts, LLC, (CEC) to ensure independence, balance, objectivity, and scientific rigor and integrity in all their CME/CE activities. Activity planners, faculty, peer reviewers, and CEC staff must disclose to the participants any relationships with ineligible entities whose products or devices may be mentioned in this CE activity, or with the commercial supporter of this CE activity. An ineligible entity is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Financial relationships may include research grants, consultant fees, travel, advisory boards, consultancy, speakers’ bureaus, other benefits, or having a self-managed equity interest in a company.
CEC has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Tara Cumming, APRN–has disclosed that she receives salary/employment from Texas Urology Group and is an advisor or consultant to Photocure.
Terran W. Sims, MSN, ACNP-C–has disclosed that she is an advisor or consultant to Coloplast.
Anne Lizardi-Calvaresi, DNP, RNFA–has disclosed that she is on the speakers bureau for Cysview, Janssen, Tolmar, and Veracyte. She is also an advisor or consultant to Myovant Sciences and Tolmar.
Caroline Pratz, CRNP–has no relevant financial relationships to disclose in relation to the content of this activity.
Susan H. Gitzinger, PharmD, MPA–has no relevant financial relationships to disclose in relation to the content of this activity.
Bryan C. Taylor, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.
Jessica Hall–has no relevant financial relationships to disclose in relation to the content of this activity.
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CEC, the faculty, and any commercial supporter of this activity do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity is designated for 1.0 contact hour.
Upon completion of a CNE request form, statements of credit for nurses will be issued within 30 business days.
ONCC/ILNA Certification Information
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. OCN®, AOCNP®, BMTCN®, CBCN®, and CPHON® nurses may apply 1.0 point in Care Continuum, Oncologic Emergencies, Oncology Nursing Practice, Professional Practice /Performance, Psychosocial Dimensions of Care and Treatment categories.
Disclaimer: ONCC review is only for designating content to be used for recertification points and is not for CNE accreditation. CNE programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC.
- 1.00 ANCC
- 1.00 Participation